Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Inhibition of diabetic nephropathy by a decoy peptide corresponding to the “handle” region for nonproteolytic activation of prorenin
Atsuhiro Ichihara, … , Tadashi Inagami, Takao Saruta
Atsuhiro Ichihara, … , Tadashi Inagami, Takao Saruta
Published October 15, 2004
Citation Information: J Clin Invest. 2004;114(8):1128-1135. https://doi.org/10.1172/JCI21398.
View: Text | PDF
Article Metabolism

Inhibition of diabetic nephropathy by a decoy peptide corresponding to the “handle” region for nonproteolytic activation of prorenin

  • Text
  • PDF
Abstract

We found that when a site-specific binding protein interacts with the “handle” region of the prorenin prosegment, the prorenin molecule undergoes a conformational change to its enzymatically active state. This nonproteolytic activation is completely blocked by a decoy peptide with the handle region structure, which competitively binds to such a binding protein. Given increased plasma prorenin in diabetes, we examined the hypothesis that the nonproteolytic activation of prorenin plays a significant role in diabetic organ damage. Streptozotocin-induced diabetic rats were treated with subcutaneous administration of handle region peptide. Metabolic and renal histological changes and the renin-Ang system components in the plasma and kidneys were determined at 8, 16, and 24 weeks following streptozotocin treatment. Kidneys of diabetic rats contained increased Ang I and II without any changes in renin, Ang-converting enzyme, or angiotensinogen synthesis. Treatment with the handle region peptide decreased the renal content of Ang I and II, however, and completely inhibited the development of diabetic nephropathy without affecting hyperglycemia. We propose that the nonproteolytic activation of prorenin may be a significant mechanism of diabetic nephropathy. The mechanism and substances causing nonproteolytic activation of prorenin may serve as important therapeutic targets for the prevention of diabetic organ damage.

Authors

Atsuhiro Ichihara, Matsuhiko Hayashi, Yuki Kaneshiro, Fumiaki Suzuki, Tsutomu Nakagawa, Yuko Tada, Yukako Koura, Akira Nishiyama, Hirokazu Okada, M. Nasir Uddin, A.H.M. Nurun Nabi, Yuichi Ishida, Tadashi Inagami, Takao Saruta

×

Figure 7

Options: View larger image (or click on image) Download as PowerPoint
Changes in mRNA components of the kidney RAS in C rats (white bars, n = ...
Changes in mRNA components of the kidney RAS in C rats (white bars, n = 6), C + HRP rats (light gray bars, n = 6), DM rats (black bars, n = 6), and DM + HRP rats (dark gray bars, n = 6). (A) Kidney renin mRNA level. The graph shows a decreased kidney renin mRNA level in the DM rats up to 20 weeks of age. HRP did not affect the kidney renin mRNA level in either control or diabetic rats. (B) Kidney ACE mRNA level. The graph shows a decrease in kidney ACE mRNA level at 28 weeks of age in both the control and diabetic rats. HRP did not affect the kidney ACE mRNA level in either control or diabetic rats. (C) Kidney angiotensinogen mRNA level. The graph shows a decrease in kidney angiotensinogen mRNA level with age. HRP did not affect the kidney angiotensinogen mRNA level in either control or diabetic rats. (D) Kidney cathepsin B mRNA level. The graph shows a decreased kidney cathepsin B mRNA level in the DM rats. HRP did not affect the kidney cathepsin B mRNA level in either control or diabetic rats. *P < 0.05 for diabetic versus control rats.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts